Mersana Therapeutics Statistics Share Statistics Mersana Therapeutics has 4.99M
shares outstanding. The number of shares has increased by 1.59%
in one year.
Shares Outstanding 4.99M Shares Change (YoY) 1.59% Shares Change (QoQ) 0% Owned by Institutions (%) 71.18% Shares Floating 3.87M Failed to Deliver (FTD) Shares 939 FTD / Avg. Volume 0.77%
Short Selling Information The latest short interest is 7.92M, so 6.36% of the outstanding
shares have been sold short.
Short Interest 7.92M Short % of Shares Out 6.36% Short % of Float 6.94% Short Ratio (days to cover) 2.81
Valuation Ratios The PE ratio is -2.53 and the forward
PE ratio is -0.19.
Mersana Therapeutics's PEG ratio is
0.04.
PE Ratio -2.53 Forward PE -0.19 PS Ratio 4.33 Forward PS 0.7 PB Ratio -18.43 P/FCF Ratio -2.12 PEG Ratio 0.04
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Mersana Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.19,
with a Debt / Equity ratio of -3.01.
Current Ratio 2.19 Quick Ratio 2.19 Debt / Equity -3.01 Debt / EBITDA -0.45 Debt / FCF -0.35 Interest Coverage -18.93
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $397.03K Profits Per Employee $-678.35K Employee Count 102 Asset Turnover 0.28 Inventory Turnover n/a
Taxes Income Tax 418K Effective Tax Rate -0.61%
Stock Price Statistics The stock price has increased by -83.15% in the
last 52 weeks. The beta is 0.82, so Mersana Therapeutics's
price volatility has been higher than the market average.
Beta 0.82 52-Week Price Change -83.15% 50-Day Moving Average 8.29 200-Day Moving Average 21.47 Relative Strength Index (RSI) 37.15 Average Volume (20 Days) 122,434
Income Statement In the last 12 months, Mersana Therapeutics had revenue of 40.5M
and earned -69.19M
in profits. Earnings per share was -14.
Revenue 40.5M Gross Profit 40.5M Operating Income -73.34M Net Income -69.19M EBITDA -63.27M EBIT -64.9M Earnings Per Share (EPS) -14
Full Income Statement Balance Sheet The company has 107.75M in cash and 28.6M in
debt, giving a net cash position of 79.15M.
Cash & Cash Equivalents 107.75M Total Debt 28.6M Net Cash 79.15M Retained Earnings -895.55M Total Assets 112.47M Working Capital 48.03M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -82.34M
and capital expenditures -132K, giving a free cash flow of -82.47M.
Operating Cash Flow -82.34M Capital Expenditures -132K Free Cash Flow -82.47M FCF Per Share -16.83
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -181.09% and -170.86%.
Gross Margin 100% Operating Margin -181.09% Pretax Margin -169.82% Profit Margin -170.86% EBITDA Margin -156.24% EBIT Margin -181.09% FCF Margin -203.65%
Dividends & Yields MRSN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for MRSN is $125,
which is 1990.3% higher than the current price. The consensus rating is "Buy".
Price Target $125 Price Target Difference 1990.3% Analyst Consensus Buy Analyst Count 5
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jul 28, 2025. It was a
backward
split with a ratio of 1:25.
Last Split Date Jul 28, 2025 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -12.55 Piotroski F-Score 2
